Kazia Therapeutics Limited Successfully Closes Oversubscribed Public Offering of Up to $120 Million

Kazia Therapeutics Limited Successfully Closes Public Offering

Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company with a focus on oncology, has recently completed the closing of its highly successful public offering, which was oversubscribed and generated approximately $40 million in gross proceeds upfront. This initiative demonstrates investor confidence in Kazia, particularly in its mission to develop innovative therapies aimed at overcoming cancer treatment resistance and restoring anti-tumor immunity.

Details of the Offering

The public offering consisted of the sale of 2,580,000 American Depositary Shares (ADSs), equivalent to 500 ordinary shares each. In addition to the ADSs, the offering included Series A and Series B Warrants, allowing investors to purchase additional shares at specified exercise prices related to significant future milestones. The Series A Warrants are linked to the Company's upcoming data readout for Stage IV triple-negative breast cancer (TNBC), while the Series B Warrants are contingent on data for HR+/HER2- breast cancer. The exercise prices of the warrants are set at $17.825 and $19.375 per ADS, respectively.

If all warrants are exercised, Kazia anticipates that the total gross proceeds from this offering could reach approximately $120 million, providing vital funding for its clinical programs. Notably, the offering attracted considerable interest from institutional investors, with notable participants including ADAR1 Capital Management and Columbia Threadneedle Investments, among others.

Future Applications of Funds

Kazia intends to utilize the net proceeds from the offering primarily for advancing the clinical development of its lead asset, paxalisib. This investigational drug is currently focused on treating multiple forms of cancer, with ongoing studies in triple-negative breast cancer, HR+/HER2- breast cancer, and pMMR colorectal cancer. Furthermore, the funds will support general corporate purposes and working capital needs.

Corporate Update Call Planned

In light of this successful offering, Kazia Therapeutics will host a corporate update call on September 1, 2026, at 8:00 AM ET. Investors can access the conference call through a provided link on the company's investor relations page or by dialing specific teleconference numbers.

About Kazia Therapeutics

Based in Sydney, Australia, Kazia Therapeutics is dedicated to drug development with a focus on oncology. Their primary investigational product, paxalisib, is known for its ability to penetrate the blood-brain barrier and target the PI3K/Akt/mTOR pathway, which is crucial in various cancer types. The drug has been involved in over 15 clinical trials and has received several designations from the FDA, including Orphan Drug and Fast Track Designations for certain conditions. The company is also exploring additional innovative therapies aimed at enhancing treatment effectiveness and addressing the challenges of treatment resistance in oncology.

Kazia's ongoing commitment to research and development emphasizes its strategic direction in the oncology space, as they strive to enhance treatment outcomes for patients facing challenging cancers. More information can be found at Kazia's website or on their social media accounts.